63 related articles for article (PubMed ID: 38474231)
21. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
22. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
23. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
25. Treatment implications of the emerging molecular classification system for melanoma.
Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy in melanoma.
Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
[TBL] [Abstract][Full Text] [Related]
27. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy to monitor melanoma patients.
Gaiser MR; von Bubnoff N; Gebhardt C; Utikal JS
J Dtsch Dermatol Ges; 2018 Apr; 16(4):405-414. PubMed ID: 29512873
[TBL] [Abstract][Full Text] [Related]
29. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
30. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
31. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
Fedorenko IV; Gibney GT; Smalley KS
Oncogene; 2013 Jun; 32(25):3009-18. PubMed ID: 23069660
[TBL] [Abstract][Full Text] [Related]
32. Current status and future direction in the management of malignant melanoma.
Gladfelter P; Darwish NHE; Mousa SA
Melanoma Res; 2017 Oct; 27(5):403-410. PubMed ID: 28800028
[TBL] [Abstract][Full Text] [Related]
33. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
Johnpulle RA; Johnson DB; Sosman JA
Curr Oncol Rep; 2016 Jan; 18(1):6. PubMed ID: 26743513
[TBL] [Abstract][Full Text] [Related]
34. The Emerging Therapeutic Landscape of Advanced Melanoma.
Henriques V; Martins T; Link W; Ferreira BI
Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407
[TBL] [Abstract][Full Text] [Related]
35. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.
Brouwer NJ; Verdijk RM; Heegaard S; Marinkovic M; Esmaeli B; Jager MJ
Prog Retin Eye Res; 2022 Jan; 86():100971. PubMed ID: 34015548
[TBL] [Abstract][Full Text] [Related]
36. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract][Full Text] [Related]
37. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
38. Targeting mutant NRAS signaling pathways in melanoma.
Vu HL; Aplin AE
Pharmacol Res; 2016 May; 107():111-116. PubMed ID: 26987942
[TBL] [Abstract][Full Text] [Related]
39. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
Lo JA; Fisher DE
Science; 2014 Nov; 346(6212):945-9. PubMed ID: 25414302
[TBL] [Abstract][Full Text] [Related]
40. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
